Jio Platforms IPO Review 2026: GMP, Financials & Valuation
Jio Platforms IPO review 2026: Check price band, dates, GMP, financial performance, ₹10.3 lakh crore valuation, strengths and key risks for investors.
Read FullArchive of all the blogs posted
Showing 12 articles this pageJio Platforms IPO review 2026: Check price band, dates, GMP, financial performance, ₹10.3 lakh crore valuation, strengths and key risks for investors.
Read FullAfter a 10-year wait, the NSE IPO is finally here. Get a complete review of the National Stock Exchange price band, financials, valuation, risks, and latest GMP.
Read FullNSE has filed for its long-awaited IPO. Before applying, understand its valuation, F&O dependence, regulatory risks and 100% OFS structure.
Read FullTata Sons remains an Upper Layer NBFC in 2026. Understand RBI listing rules, CIC deregistration, IPO deadline and what could happen next.
Read FullSBI Funds Management IPO: RHP-based review of price band, GMP, financials & risks, and why more than half its AUM is PMS, not mutual funds.
Read FullNSE filed its DRHP on June 17, 2026. Expected IPO size ₹30,000 crore, 100% OFS, valuation ~₹5-6 lakh crore. At 58-68x P/E on declining FY26 earnings, here is what the prospectus does not emphasise - i
Read FullTata Sons missed its RBI listing deadline. Deregistration stalled. Two Tata Trusts vice-chairmen now back listing. Full breakdown: shareholding, SP Group debt trap, and the case for going public.
Read FullFY26 saw 108 mainboard IPOs raise ₹1,75,186 crore - a record. Yet 71 of those IPOs are below their issue price. Here is the full performance breakdown, subscription data, and what it means for investo
Read FullOmnitech Engineering IPO review 2026: issue size, price band, lot size, order book, business model, financials, valuation (EPS/P-E), use of proceeds for new facilities, key risks, and who it may suit.
Read FullPNGS Reva Diamond Jewellery IPO review 2026: price band, lot size, business model (FOCO/FOFO/COCO), financials, valuation, use of proceeds for 15 new stores, key risks, and who it may suit. Educationa
Read FullGaudium IVF IPO review covering business model, financials, valuation, GMP, use of proceeds, risks, and who this Gaudium IVF stock may suit. A neutral, data-backed analysis for retail investors.
Read FullFractal Analytics IPO review covering business model, financials, valuation, GMP, use of proceeds, risks, and who this AI-led company may suit. A neutral, data-backed analysis for retail investors.
Read Full